A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

计划入组 30 人 · 首次发布于 2024 年 4 月 15 日

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

计划入组 212 人 · 首次发布于 2018 年 9 月 12 日

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

计划入组 40 人 · 首次发布于 2024 年 3 月 26 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

H & H EXPORTS, LLC

United States

LG H&H Co., Ltd.

South Korea

Marengo Secures ESMO 2026 Oral Presentation for Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors, Appoints KEYTRUDA Development Leader Eric Rubin to Scientific Advisory Board

Invikafusp Alfa Shows Promise in Checkpoint Inhibitor-Resistant Solid Tumors with High Disease Control Rates

Controversy Surrounds FDA Approval of Pembrolizumab for High TMB Solid Tumors